Project Grant R44AI195231
Award Date 8/1/26
Completion Date 1/31/27
Dollars Obligated $300K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ithaca, NY, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Vivid Bioinnovations, PBC $307,074 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop HIVE-SEQ, a novel omics platform for profiling single HIV-infected cells. HIVE-SEQ integrates the intact proviral DNA assay with single-cell and single-nucleus multi-omic profiling to identify and characterize cells carrying viable HIV proviruses across diverse tissues without requiring viral...
- The National Institute of Allergy and Infectious Diseases awarded New York University $841,719 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop low-cost rapid antibody tests for monitoring HIV treatment effectiveness as a complement to conventional PCR viral load testing. The research consolidates quantitative antibody data across 13 assay platforms and 17 longitudinal HIV treatment cohorts spanning 10 countries and all major HIV subtypes. The...
- The National Institute of Allergy and Infectious Diseases awarded Vivid Bioinnovations, PBC $299,991 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a spatially resolved single-cell DNA sequencing platform for spatial genomics with application to HIV reservoir mapping. The recipient will develop the first commercially viable spatial genomics platform integrating hydrogel-based spatial barcoding, droplet microfluidics, and Bayesian...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $781,073 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop interventions that silence HIV-1 and reduce viral reservoir persistence following antiretroviral therapy initiation. The research develops a new intervention using ectopic expression of an HIV-1-encoded antisense transcript (AST) delivered before ART initiation or restart. The work aims to...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $1.506 million on September 16, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a human factors-designed point-of-care test for simultaneous detection of HIV, HBV, and HCV viral loads in whole blood. The award funds development of a microfluidic cartridge, molecular biology method, biosensor using crumpled graphene readout, and detection instrument capable of...
- The National Institute of Allergy and Infectious Diseases awarded $297,000 to Texas Biomedical Research Institute on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research on targeting super-enhancers to regulate HIV transcription and latency. The project, identified as R21AI203697, will define molecular mechanisms by which super-enhancer-associated long non-coding RNAs (SE-lncRNAs) regulate HIV transcription and maintain viral latency in...
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $162,000 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the single-cell epigenetic landscape of the HIV-1 reservoir for effective latency reversal. The research will characterize proviral epigenetics—the regulation of transcription at the chromatin level independent of DNA sequence—to understand how latent HIV is established,...
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $894,998 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate intrinsic CD4 T cell barriers to HIV-1 latency reversal. The research addresses HIV-1 persistence in CD4 T cells despite effective antiretroviral therapy by examining post-transcriptional mechanisms that constrain productive viral gene expression. The investigator will integrate...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $511,531 on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance HIV vaccine development using a lipid nanodisc platform. The project, designated R01AI192143, addresses challenges in engineering transmembrane HIV envelope glycoprotein (ENV) vaccine candidates by incorporating them into stable lipid nanodiscs using membrane scaffold proteins and...
- The National Institute of Allergy and Infectious Diseases awarded J. David Gladstone Institutes $896,029 on July 15, 2026, for UNDO-HIV: Understanding and Obliterating the Active HIV Reservoir, a Project Grant supported under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds development and application of three single-cell and imaging technologies to characterize HIV reservoir cells that actively express viral proteins while persisting despite antiretroviral...